Literature DB >> 26530743

A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927).

Gregory M M Videtic1, Chen Hu2, Anurag K Singh3, Joe Y Chang4, William Parker5, Kenneth R Olivier6, Steven E Schild7, Ritsuko Komaki4, James J Urbanic8, Robert D Timmerman, Hak Choy9.   

Abstract

PURPOSE: To compare 2 stereotactic body radiation therapy (SBRT) schedules for medically inoperable early-stage lung cancer to determine which produces the lowest rate of grade ≥3 protocol-specified adverse events (psAEs) at 1 year. METHODS AND MATERIALS: Patients with biopsy-proven peripheral (≥2 cm from the central bronchial tree) T1 or T2, N0 (clinically node negative by positron emission tomography), M0 tumors were eligible. Patients were randomized to receive either 34 Gy in 1 fraction (arm 1) or 48 Gy in 4 consecutive daily fractions (arm 2). Rigorous central accreditation and quality assurance confirmed treatment per protocol guidelines. This study was designed to detect a psAEs rate >17% at a 10% significance level (1-sided) and 90% power. Secondary endpoints included rates of primary tumor control (PC), overall survival (OS), and disease-free survival (DFS) at 1 year. Designating the better of the 2 regimens was based on prespecified rules of psAEs and PC for each arm.
RESULTS: Ninety-four patients were accrued between September 2009 and March 2011. The median follow-up time was 30.2 months. Of 84 analyzable patients, 39 were in arm 1 and 45 in arm 2. Patient and tumor characteristics were balanced between arms. Four (10.3%) patients on arm 1 (95% confidence interval [CI] 2.9%-24.2%) and 6 (13.3%) patients on arm 2 (95% CI 5.1%-26.8%) experienced psAEs. The 2-year OS rate was 61.3% (95% CI 44.2%-74.6%) for arm 1 patients and 77.7% (95% CI 62.5%-87.3%) for arm 2. The 2-year DFS was 56.4% (95% CI 39.6%-70.2%) for arm 1 and 71.1% (95% CI 55.5%-82.1%) for arm 2. The 1-year PC rate was 97.0% (95% CI 84.2%-99.9%) for arm 1 and 92.7% (95% CI 80.1%-98.5%) for arm 2.
CONCLUSIONS: 34 Gy in 1 fraction met the prespecified criteria and, of the 2 schedules, warrants further clinical research.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26530743      PMCID: PMC4744654          DOI: 10.1016/j.ijrobp.2015.07.2260

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  25 in total

1.  Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study.

Authors:  Hiroshi Onishi; Hiroki Shirato; Yasushi Nagata; Masahiro Hiraoka; Masaharu Fujino; Kotaro Gomi; Yuzuru Niibe; Katsuyuki Karasawa; Kazushige Hayakawa; Yoshihiro Takai; Tomoki Kimura; Atsuya Takeda; Atsushi Ouchi; Masato Hareyama; Masaki Kokubo; Ryusuke Hara; Jun Itami; Kazunari Yamada; Tsutomu Araki
Journal:  J Thorac Oncol       Date:  2007-07       Impact factor: 15.609

2.  Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy.

Authors:  Clint Park; Lech Papiez; Shichuan Zhang; Michael Story; Robert D Timmerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-01       Impact factor: 7.038

3.  Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.

Authors:  Robert Timmerman; Ronald McGarry; Constantin Yiannoutsos; Lech Papiez; Kathy Tudor; Jill DeLuca; Marvene Ewing; Ramzi Abdulrahman; Colleen DesRosiers; Mark Williams; James Fletcher
Journal:  J Clin Oncol       Date:  2006-10-20       Impact factor: 44.544

4.  Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors.

Authors:  Quynh-Thu Le; Billy W Loo; Anthony Ho; Christian Cotrutz; Albert C Koong; Heather Wakelee; Stephen T Kee; Dana Constantinescu; Richard I Whyte; Jessica Donington
Journal:  J Thorac Oncol       Date:  2006-10       Impact factor: 15.609

5.  Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer.

Authors:  Joe Y Chang; Peter A Balter; Lei Dong; Qiuan Yang; Zhongxing Liao; Melenda Jeter; M Kara Bucci; Mary F McAleer; Reza J Mehran; Jack A Roth; Ritsuko Komaki
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-11-15       Impact factor: 7.038

6.  Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer.

Authors:  Frank J Lagerwaard; Cornelis J A Haasbeek; Egbert F Smit; Ben J Slotman; S Senan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-31       Impact factor: 7.038

7.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

8.  Stereotactic single-dose radiotherapy (radiosurgery) of early stage nonsmall-cell lung cancer (NSCLC).

Authors:  Holger Hof; Marc Muenter; Dieter Oetzel; Angelika Hoess; Juergen Debus; Klaus Herfarth
Journal:  Cancer       Date:  2007-07-01       Impact factor: 6.860

9.  Practical considerations arising from the implementation of lung stereotactic body radiation therapy (SBRT) at a comprehensive cancer center.

Authors:  Max Dahele; Shannon Pearson; Tom Purdie; Jean-Pierre Bissonnette; Kevin Franks; Anthony Brade; John Cho; Alex Sun; Andrew Hope; Andrea Marshall; Jane Higgins; Andrea Bezjak
Journal:  J Thorac Oncol       Date:  2008-11       Impact factor: 15.609

10.  Clinical outcome of stereotactic body radiotherapy of 54 Gy in nine fractions for patients with localized lung tumor using a custom-made immobilization system.

Authors:  Masahiko Aoki; Yoshinao Abe; Hidehiro Kondo; Yoshiomi Hatayama; Hideo Kawaguchi; Akira Fujimori; Katsumasa Suzaki; Morio Seino; Takeshi Morita; Makoto Souma; Takao Tsushima; Shingo Takanashi
Journal:  Radiat Med       Date:  2007-07-27
View more
  116 in total

1.  Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer.

Authors:  Gregory M Videtic; Rebecca Paulus; Anurag K Singh; Joe Y Chang; William Parker; Kenneth R Olivier; Robert D Timmerman; Ritsuko R Komaki; James J Urbanic; Kevin L Stephans; Sue S Yom; Clifford G Robinson; Chandra P Belani; Puneeth Iyengar; Munther I Ajlouni; Darindra D Gopaul; Jorge B Gomez Suescun; Ronald C McGarry; Hak Choy; Jeffrey D Bradley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-12-01       Impact factor: 7.038

2.  Thoracic target volume delineation using various maximum-intensity projection computed tomography image sets for radiotherapy treatment planning.

Authors:  David A Zamora; Adam C Riegel; Xiaojun Sun; Peter Balter; George Starkschall; Osama Mawlawi; Tinsu Pan
Journal:  Med Phys       Date:  2010-11       Impact factor: 4.071

3.  Cortical Thinning and Structural Bone Changes in Non-Human Primates after Single-Fraction Whole-Chest Irradiation.

Authors:  Michael Farris; Emory R McTyre; Catherine Okoukoni; Greg Dugan; Brendan J Johnson; A William Blackstock; Michael T Munley; J Daniel Bourland; J Mark Cline; Jeffrey S Willey
Journal:  Radiat Res       Date:  2018-05-08       Impact factor: 2.841

Review 4.  Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.

Authors:  Meghan Campo; Hani Al-Halabi; Melin Khandekar; Alice T Shaw; Lecia V Sequist; Henning Willers
Journal:  Oncologist       Date:  2016-06-27

5.  Central Airway Toxicity After High Dose Radiation: A Combined Analysis of Prospective Clinical Trials for Non-Small Cell Lung Cancer.

Authors:  Weili Wang; Martha M Matuszak; Chen Hu; Ke Colin Huang; Eileen Chen; Douglas Arenberg; Jeffrey L Curtis; Shruti Jolly; Jian-Yue Jin; Mitchell Machtay; Randall K Ten Haken; Feng-Ming Spring Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-05-26       Impact factor: 7.038

Review 6.  Establishing the Impact of Vascular Damage on Tumor Response to High-Dose Radiation Therapy.

Authors:  Katherine D Castle; David G Kirsch
Journal:  Cancer Res       Date:  2019-08-19       Impact factor: 12.701

7.  Predictors of Nodal and Metastatic Failure in Early Stage Non-small-cell Lung Cancer After Stereotactic Body Radiation Therapy.

Authors:  Alberto Cerra-Franco; Sheng Liu; Michella Azar; Kevin Shiue; Samantha Freije; Jason Hinton; Christopher R Deig; Donna Edwards; Neil C Estabrook; Susannah G Ellsworth; Ke Huang; Khalil Diab; Mark P Langer; Richard Zellars; Feng-Ming Kong; Jun Wan; Tim Lautenschlaeger
Journal:  Clin Lung Cancer       Date:  2018-12-29       Impact factor: 4.785

8.  One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial.

Authors:  Anurag K Singh; Jorge A Gomez-Suescun; Kevin L Stephans; Jeffrey A Bogart; Gregory M Hermann; Lili Tian; Adrienne Groman; Gregory M Videtic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-08-22       Impact factor: 7.038

9.  An image-based deep learning framework for individualizing radiotherapy dose.

Authors:  Bin Lou; Semihcan Doken; Tingliang Zhuang; Danielle Wingerter; Mishka Gidwani; Nilesh Mistry; Lance Ladic; Ali Kamen; Mohamed E Abazeed
Journal:  Lancet Digit Health       Date:  2019-06-27

10.  Initial characterization of a gel patch dosimeter for in vivo dosimetry.

Authors:  C Matrosic; W Culberson; B Rosen; E Madsen; G Frank; B Bednarz
Journal:  Phys Med Biol       Date:  2016-04-18       Impact factor: 3.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.